Formycon trials ranibizumab

Formycon says it and licensee Bioeq have achieved an “important milestone” for their FYB201 proposed biosimilar rival to Lucentis (ranibizumab) after reporting Phase III study results that show “comparable efficacy between FYB201 and Lucentis” in patients with neovascular age-related macular degeneration.